Neurology

We’re unlocking the science of neuroimmunology, striving to help people impacted by neurological diseases so they can live for the moment, not for the disease.
Julie, a person living with multiple sclerosis and her family, United States
Julie, a person living with multiple sclerosis and her family, United States
People living with neurological disorders need new high-efficacy treatment options that help to address their unmet needs. Through research and scientific innovation, we are committed to breaking barriers in the neurological space.
Erik Wallstroem

Erik Wallstroem

Global Head of Neurology Development

Did You Know

1/3

of people are affected by neurological disorders, which are now the leading cause of ill health and disability worldwide.1

~2.9 million

people worldwide are estimated to live with multiple sclerosis (MS).2

30%

of people living with CIDP do not respond to standard treatments.3

Cassie, multiple sclerosis, Australia
Cassie, multiple sclerosis, Australia

Our Commitment to Neurology

Since 2012, our goal has been to improve the lives of people with serious neuro-inflammatory and neuro-degenerative diseases. We are testing the bounds of clinical possibility to research therapies that may address multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), Alzheimer’s Disease (AD), Parkinson’s disease (PD), Age-Related Macular Degeneration (AMD) and other neurological diseases for the people who need them most.

Dave, multiple sclerosis, United Kingdom
Dave, multiple sclerosis, United Kingdom

Our Neurology Focus

By embracing the challenges seen in neurological diseases, we’re working to advance care, extending our leadership in immunoscience to help address areas of unmet need in neurodegeneration and neuroinflammation. Through our innovative partnerships and technologies, we strive to decrease the burden of neurological diseases on people and society.

Our neuroimmunology programs are built on a strong foundation of long-term partnerships with patients, physicians, advocates and researchers. Our goal is to slow or even halt neurodegeneration in MS, CIDP, AD, PD, AMD and other neurological diseases.

Microscopic view of nerves
Microscopic view of nerves

What’s Next in Neurology?

For almost two decades, we’ve worked relentlessly to deliver disease-modifying therapies for MS with distinct indications and mechanisms of action.4

We’re building on the success of our medicines, used to treat MS patients in more than 80 countries, and our foundation as a leading immunology company, to research and design therapies with “best-in-class” potential. By uncovering the biology behind neuroinflammatory disease, we may be able to unlock therapies that address the diseases with the greatest unmet need.

More About Neurology

Neurology Research and Development

Neuroimmunology Unlocks the Mysteries of the Brain

Why Smoldering Neuroinflammation Must Be Part of the Discussion to Improve Care in Multiple Sclerosis

References

  1. GBD 2021 Nervous System Disorders Collaborators. (2021). Global, regional and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurology P344-381; DOI: https://doi.org/10.1016/S1474-4422(24)00038-3
  2. Multiple Sclerosis International Federation (2023). Atlas of MS. Accessed July 2023
  3. National Organization for Rare Disorders, Inc. Chronic inflammatory demyelinating polyneuropathy. Available at:  https://rarediseases.org/rare-diseases/chronic-inflammatory-demyelinating-polyneuropathy/
  4. See Aubagio (teriflunomide) Summary of Product Characteristics, May 2021; Lemtrada (alemtuzumab) Summary of Product Characteristics, August 2021; and Cohen JA, et al. (2012) Lancet 380:1819-28; DOI: 10.1016/S0140-6736(12)61769-3


Page updated September 2024

MAT-GLB-2405337 v1.0